Skip to content
Vistoa
FeedTopics
Sign inSign up
Top StoriesUnited StatesCanadaWorldPoliticsGeneralBusinessTechHealthSportsEntertainmentAviationPublishers

NPF Primer: GLP-1s Worth Considering as Adjunct for Select Psoriasis Patients

1 articles · 1 outlets · spread 0.00

NPF Primer: GLP-1s Worth Considering as Adjunct for Select Psoriasis Patients
medicine18 hr ago

NPF Primer: GLP-1s Worth Considering as Adjunct for Select Psoriasis Patients

Full coverage view across outlets, lean, source quality, and framing. Compare framing without algorithmic ranking.

1 articles1 outletsSpread 0.0012 claims
Vistoa

Article-level news analysis, transparent scoring, and API tools for readers, publishers, and teams that need source context.

DMCA and copyright review

Copyright owners can submit notices, counter-notices, and source material concerns through the dedicated review flow.

Open DMCA review

Product

  • Home
  • Feed
  • Search
  • Topics
  • Saved

Platform

  • About
  • Methodology
  • Home
  • Search
  • Saved
  • Me

From the Left

0 outlets

No coverage from this perspective yet.

From the Center

1 outlet
  • MedPage Today·May 3

    NPF Primer: GLP-1s Worth Considering as Adjunct for Select Psoriasis Patients

    Available evidence suggests GLP-1 receptor agonists warrant consideration as an adjunct to conventional treatments for psoriasis.Multiple studies have shown that GLP-1 receptor agonists improve psoriasis disease status and quality of life.The greatest benefits occur in patients with obesity, as weight loss appears to enhance effects of psoriasis medications. GLP-1 receptor agonists represent a "biologically plausible and clinically intriguing adjunct" to psoriasis therapy for selected patients, authors of a National Psoriasis Foundation (NPF) "primer" concluded. The evidence showed that GLP-1 agonists and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 agents have been associated with clinically meaningful reductions in the Psoriasis Area and Severity Index (PASI), accompanied by improvements in quality of life. Additionally, semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda) have been associated with reductions in C-reactive protein, interleukin-6, lipids, and visceral adiposity. Small translational studies have shown correlations between improvement in PASI scores and reductions in superficial adiposity and dermal γδ T-cell density. GLP-1 receptor agonists can be combined safely with methotrexate, cyclosporine, and biological agents used to treat psoriatic diseases. Preliminary data have shown both metabolic and immunomodulatory benefits, the authors stated in JAMA Dermatology. "We think the paper is important because it's actually addressing the question of whether dermatologists and

From the Right

0 outlets

No coverage from this perspective yet.

Claim synthesis

Pro users see canonical claims across the cluster and which outlets reported each one.

Learn more

Outlets covering this story

MedPage Today

First seen

May 3, 2026

Latest

May 3, 2026

Outlets

1

Diversity

100/100

  • Pricing
  • API docs
  • Publishers

    • Account

    • Sign in
    • Create account
    • Reader settings
    • API console

    Legal

    • Terms
    • Privacy
    • Security
    • DMCA

    © 2026 Vistoa. All rights reserved.

    Limited excerpts, attribution, analysis, and outbound publisher links remain core product boundaries.